BIAFW
bioAffinity Technologies, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$0.70
+78.74%Aug 18, 2026, 12:00 UTC
bioAffinity Technologies and AvMEDICAL announced a nationwide federal healthcare distribution agreement for CyPath Lung, expanding sales reach and access to government healthcare systems.
Source:Aug 14, 2026, 00:00 UTC
bioAffinity Technologies, Inc. completed a private placement on August 12, 2026, issuing pre-funded warrants, Series A warrants, and Series B warrants, raising approximately $4 million in gross proceeds.
Aug 7, 2026, 12:00 UTC
bioAffinity Technologies reported its financial results for the second quarter of 2026.
Source:Jul 22, 2026, 12:08 UTC
bioAffinity Technologies and Pictor, Inc. partner to develop and commercialize bioAffinity's diagnostics for asthma and COPD.
Source:Jul 7, 2026, 12:46 UTC
bioAffinity Technologies reported that quarterly sales of its CyPath Lung diagnostic doubled to a new record, with more than 200% year-over-year growth.
Source:Jun 17, 2026, 13:25 UTC
bioAffinity Technologies priced a public offering of 4,000,000 shares of common stock (or pre-funded warrants in lieu thereof) at $0.80 per share for aggregate gross proceeds of $3.2 million.